| 李小燕,王慧琴,张彬,等.微创肺表面活性物质给药技术在早产儿呼吸窘迫综合征36 例中的应用[J].安徽医药,2023,27(3):533-536. |
| 微创肺表面活性物质给药技术在早产儿呼吸窘迫综合征36 例中的应用 |
| Application of less invasive surfactant administration in 36 premature infants with respiratory distress syndrome |
| |
| DOI：10.3969/j.issn.1009-6469.2023.03.024 |
| 中文关键词: 呼吸窘迫综合征，新生儿 婴儿，早产 微创肺表面活性物质给药(LISA) 肺表面活性物质 微创技术 |
| 英文关键词: Respiratory distress syndrome, newborn Infant, premature LISA technology Pulmonary surfactant Minimally invasive technology |
| 基金项目:2020年度安徽医科大学校科研基金项目(2020xkj235)；合肥市卫生健康委2021年度应用医学研究项目(Hwk2021zd016)；中国疾病预防控制中心妇幼保健中心母婴营养与健康研究项目资助(2022FYH007) |
|
| 摘要点击次数: 1284 |
| 全文下载次数: 409 |
| 中文摘要: |
| 目的 探讨微创肺表面活性物质给药(LISA)技术在早产儿呼吸窘迫综合征(RDS)中的应用疗效及对早产儿住院期间并发症的研究。方法 回顾性分析2020年1月至2022年2月安徽省妇幼保健院收治并确诊为RDS、胎龄在25~32周的RDS早产儿82例的临床资料，根据治疗方法不同分为A组(LISA技术，36例)和B组［气管插管-肺表面活性物质-拔管(INSURE)技术，46例］。A组采用LISA技术完成肺表面活性物质(PS)给药方法，B组采用INSURE技术完成PS给药。结果 用氧总时间A组(30.67±15.03)h，B 组(39.06±18.17)h；住院总时间A 组(41.67±15.78)h，B 组(49.60±17.09)h；辅助通气总时间A 组(21.76±10.16)h，B组(28.89±13.22)h，组间均差异有统计学意义(P<0.05)。A组病儿2次PS发生率、PS反流发生率和72 h机械通气治疗率分别为0.00%(0/36)、2.78%(1/36)和5.56%(2/36)，显著低于B组的15.22%(7/46)、17.39%(8/46)和21.74%(10/46)。A组病儿气胸、有血液动力学影响的动脉导管未闭(hsPDA)、支气管肺发育不良(BPD)发生率分别为2.78%(1/36)、27.78%(10/36)和27.78%(10/36)，显著低于B组的19.57%(9/46)、50.00%(23/46)，52.17%(24/46)。结论 采用LISA技术治疗早产儿RDS可有效缓解病儿呼吸情况，保证PS用药剂量的准确性，减少住院时间、降低住院期间并发症，值得临床推广应用。 |
| 英文摘要: |
| Objective To explore the efficacy of less invasive surfactant administration (LISA) in the treatment of respiratory dis?tress syndrome (RDS) and complications during hospitalization of preterm neonates.Methods A retrospective analysis was made of the clinical data of 82 preterm infants with gestation age of 25~32 weeks and diagnosed with RDS who were admitted to Anhui Provin?cial Maternity and Child Health Hospital from January 2020 to February 2022. They were randomly assigned to group A in which the administration of pulmonary surfactant (PS) was via less invasive surfactant administration (LISA, 36 cases) and group B in which the PS administration was via intubation-surfactant-extubation (INSURE, 46 cases).Results The total time of oxygen use was (30.67±15.03) h in group A and (39.06±18.17) h in group B. The total length of hospital stay of group A was (41.67±15.78) h, and that of group B was (49.60±17.09) h. The total time of auxiliary ventilation in group A and group B was (21.76±10.16) h and (28.89±13.22) h, respec?tively. The differences between groups were statistically significant (P < 0.05). The incidences of second-time PS, PS regurgitation and 72-hour mechanical ventilation in group A were 0.00% (0/36), 2.78% (1/36) and 5.56% (2/36), respectively, significantly lower than 15.22% (7/46), 17.39% (8/46) and 21.74% (10/46) in group B. The incidences of pneumothorax, hemodynamically significant patent ductus arteriosus (hsPDA) and bronchopulmonary dysplasia (BPD) in group A were 2.78% (1/36), 27.78% (10/36) and 27.78% (10/36),respectively, significantly lower than 19.57% (9/46), 50.00% (23/46) and 52.17% (24/46) in group B.Conclusion The treatment of preterm neonates with RDS via LISA can effectively relieve the respiratory status of infants, ensure the accuracy of PS medication dose,shorten the length of hospital stay, and reduce complications, which is worthy of clinical application. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
